Science | Nature | Cell | View More
Screening Libraries
Broussonetia kazinoki Sieb. et Zucc.
A unique collection of 12 Broussonetia kazinoki Sieb. et Zucc. for high throughput screening (HTS), high content screening (HCS) and New drug research
Cat. Size Price Stock
P205291mg/well * 12 CompoundsInquiry In stock
Contact Us
P20529100uL/well (10mM solution) * 12 CompoundsInquiry In stock
*You can select compounds, quantities, format (dry/solid or DMSO) and plate map to meet your specific requirement.
Contact Us
E-mail manager@chemfaces.com
Tel (0086)-27-8423-7683
Shelf Life (0086)-27-84254680
ManufacturerWuhan ChemFaces Biochemical Co., Ltd.
Package & Storage
Container 96 Well Format Sample
Storage Protected from air and light, refrigerate or freeze(2-8 °)
Shelf Life 24 months (2-8 °)
Intended UseFor research use only. Not for human use. Not sell to patients
Description & Advantages
1. The products in the ChemFaces screening libraries are all from plants.
2. The biological activities or pharmacological activities of all the ChemFaces products are derived from the databases of all over the world the latest literatures, you can according to the product manuals on our website to access the relevant literatures, hope that our informations can give some inspirations and help to your research.
3.The collections of unique natural products, which include antioxidants, anti-inflammatory, antibacterial, anticancer, and ect. Can be used for high throughput screening (HTS) and high content screening (HCS), is to help you carry out new drug screening, the emergence of new indications and other professional tools.
4.Structurally diverse, medicinally active, and cell permeable, NMR and HPLC validated to ensure high purity.
5. ChemFaces offers customized bioactive screening libraries , whereby you choose the specific compounds you want in the library, the quantities, plate map, concentration, and format (dry/solid or DMSO solution).
Natural Products
Catalog No. Information
CFN99272 Quercetin

Quercetin is one of the most prominent dietary antioxidants, it is claimed to exert beneficial health effects, this includes protection against various diseases such as osteoporosis, certain forms of cancer, pulmonary and cardiovascular diseases but also against aging. It is a stimulator of recombinant SIRT1 and also a PI3K inhibitor with IC50 of 2.4±0.6 μM, 3.0±0.0 μM and 5.4±0.3 μM for PI3K γ, PI3K δ and PI3K β, respectively. It also attenuated the function VEGFR, androgen receptor and the expressions of NF-κB, IL Receptor, FAK, ERK,Nrf2.
CFN99156 Liquiritigenin

Liquiritigenin, is an estrogenic compound which acts as an agonist selective for the β-subtype of the estrogen receptor, possesses anti-inflammatory, antihyperlipidemic, and antiallergic effects. Liquiritigenin can dose dependently alleviate mechanical, thermal and cold hyperalgesia, it may be potentially useful novel treatments for neuropathic pain. It exhibits antitumour action in pituitary adenoma cells via Ras/ERKs and ROS-dependent mitochondrial signalling pathways.
CFN98713 Daucosterol

Daucosterol has neuroprotective activity, it has proliferation-enhancing activity for neural stem cells (NSCs), may be involved in IGF1-AKT pathway, and it as an efficient and inexpensive growth factor alternative that could be potentially developed as a medicine for ischemic stroke treatment, can significantly reduce neuronal loss.Daucosterol exhibits moderate antibacterial activity against Bacillus subtilis and Staphylococcus aureus; it has anti-cancer and apoptotic effects in human colon cancer cell line HCT-116, at different doses induces cell cycle arrest at sub-G1 phase of the cell cycle.
CFN97542 Isoliquiritigenin

Isoliquiritigenin has hepatoprotective, chemopreventive, antitumor, vasorelaxant, anti-platelet, anti-allergic, antiviral, antioxidant and anti-inflammatory effects, it can induce growth inhibition and apoptosis through downregulating AA metabolic network and the deactivation of PI3K/Akt in human breast cancer. Isoliquiritigenin also has the ability to protect cells from AA+iron-induced H2O2 production and mitochondrial dysfunction, which is mediated with GSK3β phosphorylation downstream of AMPK.
CFN98776 Butein

Butein is a chelator of ferrous and copper ions, is able to inhibit the activation of protein tyrosine kinase, NF-κB and STAT3, also inhibits EGFR. Butein can inactivate PMA-activated AP-1, due to the blocking of JNK-mediated c-Jun phosphorylation through the inhibition of ATP binding. Butein has potent anticancer, anti-inflammatory, antioxidant activities, it also has a hypotensive effect, at least in part, via the inhibition of angiotensin converting enzyme.
CFN97839 Kazinol U

Kazinol U may have therapeutic value in delaying pancreatic β-cell destruction in type 1 diabetes by blocking the NF-κB pathway in pancreatic β-cells reduces cell damage. Kazinol U shows estrogenic activity with ligand-activity of estrogen receptor, transcriptional activity of estrogen -responsive element-reporter genes, it may have beneficial effects in the treatment of menopausal symptoms.
CFN97594 Isolicoflavonol

Isolicoflavonol is a potential cancer chemopreventive agent.
CFN97569 Kazinol B

Kazinol B inhibits the NO synthesis with an IC(50) of 21.6 microM. It can stimulate respiratory burst, is probably mediated by the synergism of PKC activation and [Ca2+]i elevation in rat neutrophils. Kazinol B stimulates Ca(2+) release from internal Ca(2+) store, probably through the sphingosine 1-phosphate and IP(3) signaling, and activates external Ca(2+) influx mainly through a non-store-operated Ca(2+) entry (non-SOCE) pathway. Kazinol B improves insulin sensitivity via Akt and AMPK activation in 3T3-L1 adipocytes, it might be a therapeutic candidate for diabetes mellitus.
CFN92712 Marmesin

Marmesin has hepatoprotective potential; it also has cytotoxic with a 50% lethal dose of less than 0.5 micrograms/ml, is not as mutagenic or potentially carcinogenic as are AFB1, imperatorin, or MOP with BL activation.
CFN92431 Kazinol A

Kazinol A shows strong inhibition of arachidonic acid (AA)-induced platelet aggregation. It also exhibits potent inhibition with IC50 values ranging 0.6–164 M against XOD. Kazinol A may be a candidate for the development of effective anti-cancer drug on human urinary bladder cancer, it induces cytotoxic effects in human bladder cancer cells, including the cisplatin-resistant T24R2.